To confirm that CXCR4 contributes to trastuzumab resistance, we analyzed CXCR4 protein expression in a panel of HER2 + human breast cancer cell lines that were confirmed with different sensitivities to trastuzumab [42]. Here, ERBB2 is linked to breast carcinoma.